2 Tesaro Analyst Ratings, Earnings, Dividends and Insider Trades | $TSRO | NASDAQ:TSRO | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Tesaro Company Profile (NASDAQ:TSRO) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Tesaro (NASDAQ:TSRO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Buy (Score: 2.80)Consensus Price Target: $47.00 (54.76% upside) Analysts' Ratings History for Tesaro (NASDAQ:TSRO) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/4/2014Morgan StanleyDowngradeOverweight -> Equal Weight$45.00 -> $30.00View 1/21/2014BMO Capital MarketsUpgradeMarket Perform -> Outperform$36.00 -> $46.00View 1/14/2014Deutsche BankReiterated RatingBuy$62.00View 12/23/2013Deutsche BankLower Price Target$62.00View 7/29/2013Morgan StanleySet Price TargetOverweight$29.00 -> $45.00View 6/24/2013MizuhoInitiated CoverageBuy$44.00View 6/19/2013BMO Capital MarketsDowngradeOutperform -> Market Perform$36.00View 6/7/2013Leerink SwannInitiated CoverageOutperform$36.00 -> $53.00View 6/3/2013Deutsche BankReiterated RatingBuy$45.00 -> $80.00View 5/13/2013Deutsche BankBoost Price TargetBuy$27.00 -> $45.00View 4/29/2013Morgan StanleyBoost Price TargetOverweight$22.00 -> $29.00View 4/26/2013Leerink SwannReiterated RatingOutperform$28.00 -> $36.00View 3/21/2013BMO Capital MarketsBoost Price TargetOutperform$22.00 -> $36.00View 2/6/2013Deutsche BankInitiated CoverageBuy$27.00View 1/14/2013Robert W. BairdReiterated RatingOutperform$23.00 -> $19.00View 7/24/2012BMO Capital MarketsInitiated CoverageOutperformView 7/23/2012Leerink SwannInitiated CoverageOutperformView 7/23/2012Morgan StanleyInitiated CoverageOverweight$19.00View 7/23/2012Citigroup Inc.Initiated CoverageBuyView 7/23/2012Robert W. BairdInitiated CoverageOutperform$19.00View (Data available from 3/12/2012 forward) Earnings History for Tesaro (NASDAQ:TSRO)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/19/2014Q413($0.78)($0.72)ViewN/AView 11/7/2013Q313($0.69)($0.88)ViewN/AView 7/25/2013Q2 2013($0.63)($0.67)ViewN/AView 4/25/2013Q1 2013($0.62)($0.66)ViewN/AView 2/14/2013Q4 2012($0.65)($15.41)ViewN/AView 10/25/2012($0.55)($0.52)ViewN/AView 7/26/2012($0.55)($4.11)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Tesaro (NASDAQ:TSRO)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Tesaro (NASDAQ:TSRO)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View 6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View 4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View 11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View 8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View (Data available from 1/1/2013 forward) About Tesaro TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company's marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development. Headlines: (3/6) TESARO to Present at the Barclays Global Healthcare Conference (2/19) TESARO Announces Fourth-Quarter and Full-Year 2013 Operating Results Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: TSRO CUSIP: 88156910 Key Metrics: Previous Close: $30.3750 Day Moving Average: $31.9511200 Day Moving Average: $35.264 P/E Ratio: N/AP/E Growth: 3.11Market Cap: $981.8MCurrent Quarter EPS Consensus Estimate: $-3.22 EPS Additional Links: View TSRO on Google FinanceView TSRO on Yahoo FinanceView TSRO's Company Profile on ReutersSearch for Tesaro Inc on Google Tesaro (NASDAQ:TSRO) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.